Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
Discussion with an intriguing title: "Dear long. The regulation of the pharmaceutical market in the EAEU countries: new trends, major problems and expectations was held within the framework of the XIII International Conference "Pharmaceutical business in Russia: a promising scenario for the development of the pharmaceutical market for 2018". The discussion became so vivid and lively that it lasted longer than the due date.
The channel "Pharmaceutical Education and Development” (PhED) has published two videos on drug registration procedures in the European Union. As part of a series of videos, the authors analyze the legal instruments for the protection of intellectual property: patents, trademarks, data exclusivity and market protection; they stop at evaluating options for data exclusivity and market protection of original drugs, and also talk about how to extend market protection and how to prevent abuse of a dominant market position.
Russia has developed two relatively autonomous systems of legal protection in relation to drugs.
The first is the state registration of drugs, which is carried out to ensure their safety, efficacy and quality and is regulated by the Federal Law "On Circulation of Medicines". The second is patent protection of drugs, which gives the patent owner a legal monopoly on the use of a drug that uses the patented invention. It is governed by the Civil Code. These systems are practically unrelated.
Russian National Research Medical University. N.I. Pirogov of the Ministry of Health of Russia invites you to take part in the work of the II International Conference: "The real way from scientific research to medicines", which will be held at our University October 31-November 1, 2019
According to the Hospital Audit of the Pharmaceutical Market of Russia, conducted by ZAO DSM Group (DSM Group), in the first half of 2018, for the needs of health facilities, 372.2 million packages of medicines were purchased in the amount of 92.2 billion rubles (in procurement prices) . The purchase of necessary medicines for hospitals was spent by 14.9% less than the budget in comparison with the 1st half of 2017, as a result of which the volume of purchased packages decreased by 14.7%.
Today, the topic of drug interchangeability is still actively discussed at many venues. But as a means of increasing the efficiency of public health expenditures and improving drug provision for citizens, this institute is divorced from the procurement system.
Next year it will be 10 years since the adoption of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the period up to 2020. Before its implementation, there are still two years. Sergey Tsyb, First Deputy Minister of Industry and Trade of Russia, spoke about the goals that had been achieved and which had not yet been achieved.
According to the audit of the preferential drug supply of the pharmaceutical market in Russia (ONLS and VZN) conducted by DSM Group ∗, for the first half of 2018, 43.6 million packages of drugs worth 55.1 billion rubles were purchased under the LLO program, which is 20.9 % less in value terms than the same period of the previous year, and 7.8% less in real terms.
Moscow hosts the X International Conference "What is happening in the pharmaceutical market." In the framework of the plenary session "The route is built. Government regulation as a factor in the development of the pharmaceutical industry. A new stage in the development of pharma, leading industry experts paid special attention to the discussion of the current version of the Pharma-2030 strategy.